AstraZeneca Slaps Biovail Over Seroquel XR
In its latest bid to protect two patents for Seroquel XR, AstraZeneca Pharmaceuticals LP has hit Biovail Corp. and two subsidiaries with an infringement suit over the popular treatment for bipolar...To view the full article, register now.
Already a subscriber? Click here to view full article